A hotspot of inactivation: The A22S and V108M polymorphisms individually destabilize the active site structure of catechol O-methyltransferase

Biochemistry

Volumn 48, Issue 27, 2009, Pages 6450-6460

  Rutherford, Karen ^a,c   Daggett, Valerie ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; ACTIVE SITE STRUCTURE; BINDING RESIDUES; COGNITIVE FUNCTIONS; HETEROZYGOSITY; HOT SPOT; MOLECULAR DYNAMICS SIMULATIONS; NEGATIVE CONTROL; O-METHYLTRANSFERASE; PROTEIN CORE; PROTEIN SYSTEM; S-ADENOSYLMETHIONINE; SIMULATION TIME; SOLVENT EXPOSURE; SUBSTRATE-BINDING; WILD TYPES;

DYNAMICS; ENZYMES; MOLECULAR DYNAMICS;

POLYMORPHISM;

CATECHOL METHYLTRANSFERASE;

AMINO ACID SEQUENCE; ARTICLE; COGNITION; ENZYME ACTIVE SITE; ENZYME POLYMORPHISM; ENZYME REGULATION; ENZYME STABILITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEQUENCE HOMOLOGY;

CATALYTIC DOMAIN; CATECHOL O-METHYLTRANSFERASE; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; TEMPERATURE;

EID: 67650045643     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900174v     Document Type: Article

References (76)

1. Axelrod, J., and Szara, S. (1958) Enzymic conversion of metanephrine to epinephrine. Biochim. Biophys. Acta 30, 188-189.
2. Mannisto, P. T., and Kaakkola, S. (1999) Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51, 593-628.
3. Weinshilboum, R. M., Otterness, D. M., and Szumlanski, C. L. (1999) Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39, 19-52.
4. Tenhunen, J., Salminen, M., Jalanko, A., Ukkonen, S., and Ulmanen, I. (1993) Structure of the rat catechol-O-methyltransferase gene: Separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme. DNA Cell Biol. 12, 253-263.
5. Tenhunen, J., Salminen, M., Lundstrom, K., Kiviluoto, T., Savolainen, R., and Ulmanen, I. (1994) Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem. 223, 1049-1059.
6. Rivett, A. J., Francis, A., and Roth, J. A. (1983) Localization of membrane-bound catechol-O-methyltransferase. J. Neurochem. 40, 1494-1496.
7. Rivett, A. J., and Roth, J. A. (1982) Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase. Biochemistry 21, 1740-1742.
8. Huh, M. M., and Friedhoff, A. J. (1979) Multiple molecular forms of catechol-O-methyltransferase. Evidence for two distinct forms, and their purification and physical characterization. J. Biol. Chem. 254, 299-308.
9. Bonifati, V., and Meco, G. (1999) New, selective catechol-O- methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol. Ther. 81, 1-36.
10. Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melen, K., Julkunen, I., and Taskinen, J. (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34, 4202-4210.
11. Lees, A. J. (2008) Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci. Ther. 14, 83-93.
12. Chan, D. K., Cordato, D. J., and O'Rourke, F. (2008) Management for motor and non-motor complications in late Parkinson's disease. Geriatrics 63, 22-27.
13. Factor, S. A. (2008) Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 5, 164-180.
14. Shield, A. J., Thomae, B. A., Eckloff, B. W., Wieben, E. D., and Weinshilboum, R. M. (2004) Human catechol O-methyltransferase genetic variation: Gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 9, 151-160.
15. Saito, S., Iida, A., Sekine, A., Miura, Y., Sakamoto, T., Ogawa, C., Kawauchi, S., Higuchi, S., and Nakamura, Y. (2001) Identification of 197 genetic variations in six human methyltranferase genes in the Japanese population. J. Hum. Genet. 46, 529-537.
16. Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Shaw, N., Lane, C. R., Lim, E. P., Kalyanaraman, N., Nemesh, J., Ziaugra, L., Friedland, L., Rolfe, A., Warrington, J., Lipshutz, R., Daley, G. Q., and Lander, E. S. (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22, 231-238.
17. Palmatier, M. A., Kang, A. M., and Kidd, K. K. (1999) Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 46, 557-567.
18. Weinshilboum, R. M., and Raymond, F. A. (1977) Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am. J. Hum. Genet. 29, 125-135.
19. Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., Egan, M. F., Kleinman, J. E., and Weinberger, D. R. (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75, 807-821.
20. Goodman, J. E., Jensen, L. T., He, P., and Yager, J. D. (2002) Characterization of human soluble high and low activity catechol-O- methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 12, 517-528.
21. Rutherford, K., Alphandery, E., McMillan, A., Daggett, V., and Parson, W. W. (2008) The V108M mutation decreases the structural stability of catechol O-methyltransferase. Biochim. Biophys. Acta 1784, 1098-1105.
22. Cotton, N. J., Stoddard, B., and Parson, W. W. (2004) Oxidative inhibition of human soluble catechol-O-methyltransferase. J. Biol. Chem. 279, 23710-23718.
23. Li, Y., Yao, J., Chang, M., Nikolic, D., Yu, L.,Yager, J. D., Mesecar, A. D., van Breemen, R. B., and Bolton, J. L. (2004) Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant formof catechol-O-methyltransferase. Chem.Res.Toxicol. 17, 512-520.
24. Li, Y., Yang, X., Chang, M., Yager, J. D., van Breemen, R. B., and Bolton, J. L. (2005) Functional and structural comparisons of cysteine residues in the Val108 wild type and Met108 variant of human soluble catechol O-methyltransferase. Chem.-Biol. Interact. 152, 151-163.
25. Doyle, A. E., Goodman, J. E., Silber, P. M., and Yager, J. D. (2004) Catechol-O-methyltransferase low activity genotype (COMTLL) is associated with low levels of COMT protein in human hepatocytes. Cancer Lett. 214, 189-195.
26. Doyle, A. E., and Yager, J. D. (2008) Catechol-O-methyltransferase: Effects of the val108met polymorphism on protein turnover in human cells. Biochim. Biophys. Acta 1780, 27-33.
27. Aksoy, S., Klener, J., and Weinshilboum, R. M. (1993) Catechol O-methyltransferase pharmacogenetics: Photoaffinity labelling and western blot analysis of human liver samples. Pharmacogenetics 3, 116-122.
28. Boudikova, B., Szumlanski, C., Maidak, B., and Weinshilboum, R. (1990) Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 48, 381-389.
29. Grossman, M. H., Szumlanski, C., Littrell, J. B., Weinstein, R., and Weinshilboum, R. M. (1992) Electrophoretic analysis of low and high activity forms of catechol-O-methyltransferase in human erythrocytes. Life Sci. 50, 473-480.
30. Scanlon, P. D., Raymond, F. A., and Weinshilboum, R. M. (1979) Catechol-O-methyltransferase: Thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 203, 63-65.
31. Spielman, R. S., and Weinshilboum, R. M. (1981) Genetics of red cell COMT activity: Analysis of thermal stability and family data. Am. J. Med. Genet. 10, 279-290.
32. Weinshilboum, R. M., and Dunnette, J. (1981) Thermal stability and the biochemical genetics of erythrocyte catechol-O-methyltransferase and plasma dopamine-β-hydroxylase. Clin. Genet. 19, 426-437.
33. Dawling, S., Roodi, N., Mernaugh, R. L., Wang, X., and Parl, F. F. (2001) Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: Comparison of wild-type and variant COMT isoforms. Cancer Res. 61, 6716-6722.
34. Wedren, S., Rudqvist, T. R., Granath, F., Weiderpass, E., Ingelman-Sundberg, M., Persson, I., and Magnusson, C. (2003) Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis 24, 681-687.
35. Yim, D. S., Parkb, S. K., Yoo, K. Y., Yoon, K. S., Chung, H. H., Kang, H. L., Ahn, S. H., Noh, D. Y., Choe, K. J., Jang, I. J., Shin, S. G., Strickland, P. T., Hirvonen, A., and Kang, D. (2001) Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 11, 279-286.
36. Lachman, H. M., Morrow, B., Shprintzen, R., Veit, S., Parsia, S. S., Faedda, G., Goldberg, R., Kucherlapati, R., and Papolos, D. F. (1996) Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velocardio-facial syndrome. Am. J. Med. Genet. 67, 468-472.
37. Lachman, H. M., Nolan, K. A., Mohr, P., Saito, T., and Volavka, J. (1998) Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 155, 835-837.
38. Nolan, K. A., Volavka, J., Czobor, P., Cseh, A., Lachman, H., Saito, T., Tiihonen, J., Putkonen, A., Hallikainen, T., Kotilainen, I., Rasanen, P., Isohanni, M., Jarvelin, M. R., and Karvonen, M. K. (2000) Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. Psychiatr. Genet. 10, 117-124.
39. Strous, R. D., Bark, N., Parsia, S. S., Volavka, J., and Lachman, H. M. (1997) Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: Evidence for association with aggressive and antisocial behavior. Psychiatry Res. 69, 71-77.
40. Strous, R. D., Nolan, K. A., Lapidus, R., Diaz, L., Saito, T., and Lachman, H. M. (2003) Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: A replication study. Am. J. Med. Genet., Part B 120, 29-34.
41. Diatchenko, L., Nackley, A. G., Slade, G. D., Bhalang, K., Belfer, I., Max, M. B., Goldman, D., and Maixner, W. (2006) Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125, 216-224.
42. Zubieta, J. K., Heitzeg, M. M., Smith, Y. R., Bueller, J. A., Xu, K., Xu, Y., Koeppe, R. A., Stohler, C. S., and Goldman, D. (2003) COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 299, 1240-1243.
43. Nackley, A. G., Tan, K. S., Fecho, K., Flood, P., Diatchenko, L., and Maixner, W. (2007) Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both β2- and β3-adrenergic receptors. Pain 128, 199-208.
44. Sheldrick, A. J., Krug, A., Markov, V., Leube, D., Michel, T. M., Zerres, K., Eggermann, T., and Kircher, T. (2008) Effect of COMT val158met genotype on cognition and personality. Eur. Psychiatry 23, 385-389.
45. Goldberg, T. E., Egan, M. F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, B. S., Goldman, D., and Weinberger, D. R. (2003) Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60, 889-896.
46. Meyer-Lindenberg, A., Kohn, P. D., Kolachana, B., Kippenhan, S., McInerney-Leo, A., Nussbaum, R., Weinberger, D. R., and Berman, K. F. (2005) Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 8, 594-596.
47. Li, Y., Yang, X., van Breemen, R. B., and Bolton, J. L. (2005) Characterization of two new variants of human catechol O-methyltransferase in vitro. Cancer Lett. 230, 81-89.
48. Hong, J. P., Lee, J. S., Chung, S., Jung, J., Yoo, H. K., Chang, S. M., and Kim, C. Y. (2008) New functional single nucleotide polymorphism (Ala72Ser) in the COMT gene is associated with aggressive behavior in male schizophrenia. Am. J. Med. Genet., Part B 147, 658-660.
49. Lee, S. G., Joo, Y., Kim, B., Chung, S., Kim, H. L., Lee, I., Choi, B., Kim, C., and Song, K. (2005) Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum. Genet. 116, 319-328.
50. Tanaka, Y., Hirata, H., Chen, Z., Kikuno, N., Kawamoto, K., Majid, S., Tokizane, T., Urakami, S., Shiina, H., Nakajima, K., Dhir, R., and Dahiya, R. (2007) Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Cancer Epidemiol., Biomarkers Prev. 16, 92-97.
51. Tanaka, Y., Sasaki, M., Shiina, H., Tokizane, T., Deguchi, M., Hirata, H., Hinoda, Y., Okayama, N., Suehiro, Y., Urakami, S., Kawakami, T., Kaneuchi, M., Pookot, D., Igawa, M., Okuyama, A., Ishii, N., and Dahiya, R. (2006) Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol., Biomarkers Prev. 15, 238-244.
52. Rutherford, K., Bennion, B. J., Parson, W. W., and Daggett, V. (2006) The 108M polymorph of human catechol O-methyltransferase is prone to deformation at physiological temperatures. Biochemistry 45, 2178-2188.
53. Vidgren, J., Svensson, L. A., and Liljas, A. (1994) Crystal structure of catechol O-methyltransferase. Nature 368, 354-358.
54. Rutherford, K., Le Trong, I., Stenkamp, R. E., and Parson, W. W. (2008) Crystal structures of human 108V and 108M catechol O-methyltransferase. J. Mol. Biol. 380, 120-130.
55. Alden, R. G., Parson, W. W., Chu, Z. T., and Warshel, A. (1996) Orientation of the OH dipole of tyrosine (M)210 and its effect on electrostatic energies in photosynthetic bacterial reaction centers. J. Phys. Chem. 100, 16761-16770.
56. Levitt, M. (1990) ENCAD, Energy Calculations and Dynamics , Molecular Applications Group, Palo Alto, CA, and Yeda, Rehovot, Israel.
57. Beck, D. A. C., Alonso, D. O. V., and Daggett, V. (2000-2009) ilmm, in lucem Molecular Mechanics , University of Washington, Seattle.
58. Beck, D. A., and Daggett, V. (2004) Methods for molecular dynamics simulations of protein folding/unfolding in solution. Methods 34, 112-120.
59. Levitt, M., Hirshberg, M., Sharon, R., and Daggett, V. (1995) Potential energy function and parameters for simulations of the molecular dynamics of proteins and nucleic acids in solution. Comput. Phys. Commun. 91, 215-231.
60. Levitt, M., Hirshberg, M., Sharon, R., Laidig, K. E., and Daggett, V. (1997) Calibration and testing of a water model for simulation of the molecular dynamics of proteins and nucleic acids in solution. J. Phys. Chem. B 101, 5051-5061.
61. Kell, G. S. (1967) Precise representation of volume properties of water at one atmosphere. J. Chem. Eng. Data 12, 66-69.
62. Beck, D. A., Armen, R. S., and Daggett, V. (2005) Cutoff size need not strongly influence molecular dynamics results for solvated polypeptides. Biochemistry 44, 609-616.
63. Beck, D. A., Jonsson, A. L., Schaeffer, R. D., Scott, K. A., Day, R., Toofanny, R. D., Alonso, D. O., and Daggett, V. (2008) Dynameomics: Mass annotation of protein dynamics and unfolding in water by high-throughput atomistic molecular dynamics simulations. Protein Eng., Des. Sel. 21, 353-368.
64. Armen, R. S., Bernard, B. M., Day, R., Alonso, D. O., and Daggett, V. (2005) Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 102, 13433-13438.
65. Hubbard, S. J., and Thorton, J. M. (1993) NACCESS , Department of Biochemistry and Molecular Biology, University College, London.
66. Tsuji, E., Okazaki, K., Isaji, M., and Takeda, K. (2009) Crystal structures of the Apo and Holo form of rat catechol-O-methyltransferase. J. Struct. Biol. 165, 133-139.
67. Hoel, P. G. (1954) Introduction to Mathematical Statistics, 2nd ed., John Wiley, New York.
68. Benson, N., and Daggett, V. (2008) Dynameomics: Large-Scale Assessment of Native Protein Flexibility. Protein Sci. 17, 2038-2050.
69. Masjost, B., Ballmer, P., Borroni, E., Zurcher, G., Winkler, F. K., Jakob-Roetne, R., and Diederich, F. (2000) Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT). Chemistry 6, 971-982.
70. Kaakkola, S., Gordin, A., and Mannisto, P. T. (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmacol. 25, 813-824.
71. Kaakkola, S., Teravainen, H., Ahtila, S., Rita, H., and Gordin, A. (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44, 77-80.
72. Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., Goldberg, T. E., and Weinberger, D. R. (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32, 1011-1020.
73. Apud, J. A., and Weinberger, D. R. (2007) Treatment of cognitive deficits associated with schizophrenia: Potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 21, 535-557.
74. DeVry, C. G., and Clarke, S. (1999) Polymorphic forms of the protein L-isoaspartate (D-aspartate) O-methyltransferase involved in the repair of age-damaged proteins. J. Hum. Genet. 44, 275-288.
75. Tsai, W., and Clarke, S. (1994) Amino acid polymorphisms of the human L-isoaspartyl/D-aspartyl methyltransferase involved in protein repair. Biochem. Biophys. Res. Commun. 203, 491-497.
76. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera: A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612.